This content is sponsored by Sarepta Therapeutics and is intended for US audiences only. Any other present or future content posted by the contributors, not expressly designated as “Sarepta Therapeutics-sponsored content,” is not associated with Sarepta. Dave’s son Xavier is an actual patient who is taking EXONDYS 51 (eteplirsen).
Sponsored Content
Recent Posts
- I have new criteria for when my sons participate in DMD clinical trials
- New gene therapy for OPMD shows lasting success in small US trial
- How art fosters a sense of belonging in my life with Duchenne
- First boys dosed in Phase 2 trial of oral DMD treatment SAT-3247
- Guest Voice: Despite losses from Duchenne MD, I persevere